Harrow Eye Patent-Cliff Exposure & CMS Drug Spending Portfolio
Harrow Eye (US): 16 reconciled FDA prescription therapies (19.5% 2025 to 2030 cliff risk), $53.2M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 16 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 19.5% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $53.2M |
| 2024 Medicare Part D Spend | $43.8M |
| 2024 Medicaid Spend | $9.4M |
| California HCAI SB 17 Filings | 7 WAC filings (max 527.6% 2-yr change) |